news
We unravel disease mechanisms
news
InnoSIGN starts offering OncoSIGNal pathway profiling services for clinical use in the US
news
InnoSIGN receives grant of almost €700K for ovarian cancer multicenter trial
events
Identifying mutation-independent signaling pathway activation in molecular subtypes of triple negative breast cancers
events
Meet InnoSIGN at Association for Molecular Pathology (AMP) 2023
events